» Articles » PMID: 33217870

Dynamic Change in Serum Alpha-fetoprotein Level Predicts Treatment Response and Prognosis of Alpha-fetoprotein-producing Gastric Cancer

Overview
Specialty General Medicine
Date 2020 Nov 21
PMID 33217870
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Alpha-fetoprotein (AFP)-producing gastric cancer (AFPGC) is rare and associated with a suboptimal prognosis. The aim of this retrospective study was to identify prognostic factors, with a particular focus on the dynamics of serum AFP levels during treatment, in AFPGC patients.Data of patients with pathologically diagnosed primary gastric cancer treated with various modalities electronically collected in the medical management systems of 2 hospitals (ie, Shihezi People's Hospital and Shihezi Hospital) in Shihezi city, northwest China, from January 2007 to October 2018 were reviewed. Patients with AFPGC were identified based on serum AFP levels. Associations of the change in serum AFP levels and clinicopathological parameters with treatment response, including the overall response rate and disease control rate, and outcomes, including overall survival (OS) and progression-free survival (PFS), were compared among different groups.Of 2354 patients diagnosed with gastric cancer, 96 patients with AFPGC were identified. The objective response rate and disease control rate were significantly higher in patients whose AFP level decreased by ≥50% than in patients whose AFP level decreased by <50% (68.8% vs. 40.6%, and 87.5% vs. 53.1%, respectively, both P < .05). The median OS and PFS were 32.0 (4-74) and 24.0 (1-66) months, respectively, in patients with a ≥50% decline in AFP, and 12.5 (0-69) and 9.0 (0-63) months, respectively, in those with a <50% decline in AFP (both P < .05). On univariate and multivariate analyses, tumor, node, metastasis staging classification stage, liver metastasis, curable surgery, and the decline in the serum AFP level were associated with OS and PFS.A significant decline in the serum AFP level was associated with good treatment response and prognosis in AFPGC. Along with a decline in the serum AFP level, tumor, node, metastasis staging classification stage, liver metastasis, and curable surgery were also independent factors associated with prognosis.

Citing Articles

Alpha-fetoprotein-producing intramucosal gastric cancer found during examination of metastatic lymph nodes.

Sano T, Toyokawa T, Yoshii M, Miki Y, Tamura T, Lee S Clin J Gastroenterol. 2024; 18(1):57-61.

PMID: 39562401 DOI: 10.1007/s12328-024-02064-0.


Case report: Significant response of alpha-fetoprotein-producing gastric cancer from combined chemotherapy and immunotherapy.

Da X, Juan Z, Zhijun H, Zhongchuan L Front Immunol. 2024; 15:1448875.

PMID: 39530092 PMC: 11551777. DOI: 10.3389/fimmu.2024.1448875.


Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study.

Deng T, Wang F, Zhang L, Ning T, Sun Y, Ge S Cancer Immunol Immunother. 2024; 73(8):154.

PMID: 38833154 PMC: 11150360. DOI: 10.1007/s00262-024-03743-0.


α-Fetoprotein contributes to the malignant biological properties of AFP-producing gastric cancer.

Mao X, Wang J, Luo F Open Life Sci. 2023; 18(1):20220476.

PMID: 37588998 PMC: 10426758. DOI: 10.1515/biol-2022-0476.


Long-term survival with nivolumab followed by irinotecan after total gastrectomy in alpha-fetoprotein-producing gastric cancer: a case report and review of the literature.

Ota T, Sakashita K, Sawada R, Seki K, Maeda H, Tanaka N Surg Case Rep. 2023; 9(1):71.

PMID: 37150760 PMC: 10164665. DOI: 10.1186/s40792-023-01653-4.


References
1.
Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long Z . Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol. 2010; 102(3):249-55. DOI: 10.1002/jso.21624. View

2.
Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

3.
Hwang J, Kim S, Jin J, Hong J, Kim M, Jung S . Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis. 2013; 31(1):25-32. PMC: 3892106. DOI: 10.1007/s10585-013-9606-5. View

4.
Loglio A, Iavarone M, Vigano M, Orenti A, Facchetti F, Cortinovis I . Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. Liver Int. 2019; 39(10):1964-1974. DOI: 10.1111/liv.14197. View

5.
BERGSTRAND C, CZAR B . Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 1956; 8(2):174. DOI: 10.3109/00365515609049266. View